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Cross talk between NKT and regulatory T cells (Tregs) 
in prostatic tissue of patients with benign prostatic hy-
perplasia and prostate cancer
Abstract
Background and Purpose: Regulatory T cells (Tregs) and NKT cells 
are two subpopulations of T lymphocytes that independently regulate innate 
and adaptive immunity, but there is some evidence for cross-talk between 
Tregs and NKT cells, which allow a new immunoregulatory networks. 
Activated NKT cells may modulate quantitatively and qualitatively the 
function of Tregs through IL-2-dependent mechanisms, while Tregs can 
suppress the proliferation, cytokine release and cytotoxic activity of NKT 
cells by cell-contact-dependent mechanisms. Tregs may control tumor expan-
sion at the priming, as well as the effector’s phase of T immune responses. 
Tumor cells provide antigenic stimulation of T cells and interact with the 
tumor-infiltrated innate immune cells secreting cytokines that are crucial 
for T-cell differentiation.
Patients and Methods: In this study we examined the prostate tissue 
infiltrating lymphocytes of patients with prostate cancer (PCa) and benign 
prostatic hyperplasia (BPH) by flow cytometric technique (FACSCalibur) 
for determine the number of T, B, NK, NKT and Tregs and investigate the 
local regulatory immunosurveillance which allows the tumor’s immune-
escape.
Results: Our results have shown the statistically significantly elevated 
number of Tregs in prostatic tissue and slightly diminished percentage of 
NKT cells in prostate cancer patients in comparison to patients with benign 
prostatic hyperplasia.
Conclusion: Although the exact mechanism is still unknown, increased 
infiltration of prostate tissue with T regulatory cells seems that stimulate the 
tumor to secrete factors (chemokines) that attract these cells in the tissue of 
the prostate where they achieve their anti-tumor effect and thus may con-
tribute the tumor progression.
INTRODUCTION
Over the last few years, many studies using human tissue showed a possible role of the immune system in the pathogenesis of BPH 
and PCa (1-9). Epithelial cell turnover is affected by chronic inflamma-
tion, increasing on that way the risk of malignancies on 15% worldwide 
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croenvironment includes the action of many different 
cells like macrophages and activated T lymphocytes that 
may release angiogenic factors, chemokines and proteases. 
Acute and chronic inflammation of the urogenital system 
leads to accumulation of immunocompetent cells in the 
prostate, mainly T lymphocytes and macrophages (4). 
These cells then secrete numerous cytokines (IL-2, IFN-
gamma, IL-6, IL-8, IL-15), which participate in patho-
logical changes, as well as, in the activation of infiltrating 
lymphocytes which are characteristic for BPH and PCa 
(10). Secretion of stimulatory or inhibitory cytokines by 
infiltrating lymphocytes or neoplastic cells significantly 
affects the development or suppression of the occurrence 
of BPH and PCa. Although many studies pointed to the 
potential role of infiltrating T lymphocytes in the devel-
opment and progression of BPH and PCa, the role of 
other immunocomponent cells, primarily regulatory T 
cells (Tregs) and NKT cells in the pathogenesis of BPH 
and PCa, still remains unclear. Regulatory T cells (Tregs) 
represent a diverse subpopulation of T lymphocytes that 
have a possibility to promote their actions by different 
mechanisms to regulate pathogenic and autoreactive im-
mune responses (11, 12). Naturally occurring Tregs are 
endogenous and mature within the thymus, while the 
adaptive Tregs are maturated from naive T cells and may 
differentiate into type 1 regulatory (TR1) cells, which-
have a crucial role in autoimmune disease and are char-
acterized by producing anti-inflammatory cytokine IL-10 
and subpopulation with characteristic phenotype 
CD4+CD25+FoxP3+ that converse from peripheral 
memory T cells. Adaptive Tregs with defined immuno-
suppressive properties represent Th3 cells and secrete 
transforming growth factor (TGF-beta). Double negative 
CD4–CD8–T cells which express the gamma/delta TCR 
chain represent a subset of natural killer T cells and Th2 
cells with possibility to suppress autoimmunity. Another 
small population of T cells (TCR-gd+ T cells) has g and 
d TCR chains, differs from ab+ T cells and seems to has 
a possibility to act as professional antigen-presenting cells 
(APC) and regulatory cells. These gd+ Tregs are present-
ed in peripheral tissues, digestive tract and solid tumor, 
but it is still not clear their function and presence in tu-
mor sites (13). Natural Tregs (CD25+CD4+) express dif-
ferent very important molecules for their function [Foxp3, 
cytotoxic lymphocyte-associated antigen-4 (CTLA-4), 
IL-2 receptor (IL-2R), glucocorticoid-induced tumor ne-
crosis factor related protein (GITR)], which are involved 
in their development, activation and survival (14). Ma-
nipulation with the activation or blocking of these mol-
ecules may induce different immunological response of 
tumor immunity or autoimmune disease. On the other 
side, genetic deficiency of some of these molecules in-
duces severe autoimmune diseases. Foxp3 represents a 
new transcription factor of the forkhead/winged-helix 
family and first was found as the defective gene in X-
linked recessive mutant with lethality in hemizygous 
males, associated with overproduction of proinflamma-
tory cytokines. In humans mutation of FoxP3 gene in-
duces rare, but severe syndrom IPEX (immune dysregula-
tion, polyendocrinopathy, enteropathy, X-linked 
syndrome), accompanied with autoimmune disease (type 
I diabetes mellitus, autoimmune thyroiditis, allergic der-
matitis, inflammatory bowel disease and severe infec-
tions) (15, 16). Moreover, some of these molecules are 
used to detect natural Tregs and their kinetics in different 
physiological and pathological conditions (17, 18). NKT 
cells represent a unique subpopulation of T cells and NK 
cells, sharing common markers characteristic for NK cells 
and T cells. In contrast to conventional T lymphocytes, 
NKT cells do not perform their activities through actions 
with peptide antigen presented by classical MHC-class I 
or II molecules, but recognizes glycolipids antigen pre-




The study protocols was approved by Ethics Commit-
tee of the Medical Faculty, University of Rijeka and writ-
ten informed consent was obtained for each patient in-
cluded in the study. Patients’ data and tissue samples were 
acquired in accordance with the published International 
Health Guidelines outlined in the declaration of Hel-
sinki.
Prostate tissue samples were collected from 20 patients 
(ages 62-73; mean 67 years old) undergoing radical pros-
tatectomy in the Clinic of Urology, Clinical Hospital 
Centre Rijeka, Croatia. Histopathological analysis of 
prostate tissue samples confirmed that all samples were 
carcinomas with a differentiation grade according to 
Gleason of 6 – 9. The tissues with BPH were acquired 
form 20 patients (ages 56-70; mean 63 years old) who 
underwent transvesical prostatectomy. Due to ethical rea-
sons healthy prostate tissue were not obtained for enzy-
matic digestion of the prostate tissue. Prostate tissue from 
two healthy men was obtained during autopsy, paraffin 
embedded and used for immunoflurescence staining.
None of the patients included in the study were previ-
ously treated with immunosuppressive or radiation ther-
apy and had any immunological disease, acute or chron-
ic inflammatory disease.
Isolation of prostate mononuclear  
cells
Prostate tissue samples obtained at surgery were cut 
into small pieces and digested with 0.1% collagenase type 
IV (Sigma-Aldrich, Taufkirchen, Germany) on a mag-
netic stirrer for 90 minutes at 37oC. After the digestion, 
the cell suspension was passed through 100 mm nylon 
mesh (Becton Dickinson, Franklin Lakes, USA) to re-
move tissue debris, overlaid on Lymphoprep (Nycomed 
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ly fixed and permeabilized using fixation/permeabilisa-
tion kit (BD Biosciences) according to the manufactureŕ s 
instructions. The cells were than labelled with PE-conju-
gated mAb against FoxP3 (PCH101, IgG2a) or its isotype 
control for 30 min at 4oC. Labelled cells were fixed with 
2% paraformaldehyde pH 7.4 (Kemika, Zagreb, Croatia) 
for 20 min at room temperature, washed twice in Phos-
phate Buffered Saline (PBS) [NaCl 8 g, KCl 0.2 g, Na2H-
PO4x12H20 2.87 g and KH2PO4 0.2 g (all from Kemika, 
Zagreb, Croatia) dissolved in 1 L of distilled water] and 
analyzed by flow cytometry. Dead cells were excluded by 
propidium iodide (0.5 µg/ml) and total of 10,000 cells 
was acquired by flow cytometry.
Statistical analyses
Statistical analysis was done using data analysis soft-
ware system Statistica 8.0 (StatSoft, Inc., Tulsa, OK, 
USA). Data are presented as median value and 25-75% 
(25th – 75th percentile). Outlier results are also shown. The 
difference between groups was calculated with Mann–
Whitney U-test non-parametric test and the difference 
was significant at p<0.05.
ReSULTS
To investigate the prevalence and distribution of cer-
tain lymphocyte subpopulations (T lymphocytes and 
their subpopulations, NK cells and NKT cells) in the 
prostate tissue of patients with BPH and PCa, we labeled 
paraffin preparations of prostate tissue of patients with 
Pharma AS, Oslo, Norway) and centrifuged for 20 min-
utes at 600 g. The prostate mononuclear cells were col-
lected from the interface, washed twice in Roswell Park 
Memorial Institute (RPMI) 1640 medium (Invitrogen, 
Auckland, NZ) and used for further experiments. The 
viability of the isolated mononuclear cells was over than 
95% assessed with propidium iodide 0.5 mg/ml/106 cells 
(Sigma-Aldrich, Taufkirchen, Germany) and flow cytom-
eter (FACSCalibur, Becton Dickinson, San Jose, CA, 
USA).
Antibody staining and flow cytometry 
analysis
Surface staining of prostate mononuclear cells were 
performed for 30 min at 4 oC with different combination 
of fluorescein isothiocyanate (FITC)-conjugated anti-
CD3 monoclonal antibody (mAb, mouse UCHT1, IgG1), 
FITC-conjugated anti-CD4 mAb (RPA-T4, IgG1), Phy-
coerithryn PE-conjugated anti-CD4 mAb (mouse RPA-
T4, IgG1), PE-conjugated anti-CD56 mAb (mouse B159, 
IgG1), PE labelled anti-CD8 mAb (mouse RPA-T8, 
IgG1) and allophycocyanin (APC)-conjugated anti-
CD25 mAb (BC96, IgG1). Isotype match antibodies 
were used to set negative controls for each class of anti-
body used. All the antibodies were provided from BD 
Biosciences, Erembodegen, Belgium and used at the con-
centration of 20 ml/106 cells, unless otherwise specified. 
Intracellular staining for FoxP3 was performed on the 
cells previously stained with FITC-conjugated anti-CD4 
and APC-conjugated anti-CD25 mAbs, and consequent-
Figure 1. Expression and localization of CD3+ CD56+ ,CD4+ and CD8+ cells in BPH and PCa. After deparaffinization of the sections, either 
control prostate tissue (A), BPH (B) or PCa (C), immunofluorescence assay was performed. Sections were incubated with primary antibodies 
against CD3, CD56, CD4 and CD8 over night. Then, the sections were stained with secondary reagents.
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Figure 2. The representative phenotypic profile of CD4/CD8 (dot plots) in prostatic tissue of patients with benign prostatic hyperplasia and 
prostate cancer.
BPH and PCa and prostate tissue without pathological 
changes (control tissue prostate), with fluorescent labeled 
antibodies against CD3, CD4, CD8 and CD56 mole-
cules and analyzed on a confocal microscope. In Figure 
1 may be clearly observed infiltration of stromal NK cells 
(green fluorescence) in prostate tissue of patients with 
BPH (Figure 1B) and PCa (Figure 1C) and in control 
prostate tissue (Figure 1A). Infiltration of stromal NK 
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cells in patients with PCa as in control prostate tissue was 
significantly lower than in patients with BPH. CD3 + 
cells were found only slightly in the stroma, but in epithe-
lium considerably more in the control prostate tissue and 
in prostate tissue from patients with BPH and PCa. Co-
localizations CD3 + and CD56 + cells was observed in 
the epithelium of the prostate tissues of patients with BPH 
and PCa only slightly, while in the control epithelial tissue 
of the prostate were clearly expressed. Colocalizations 
CD3 + and CD4 + and CD3 + and CD8 + cells was 
observed in the epithelium of the prostate tissues of pa-
tients with BPH, but not in prostate tissue from patients 
with PCa.
Figure 2 has shown a representative flow cytometry 
analysis of prostate tissue infiltrating lymphocytes of pa-
tients with prostate cancer (PCa) and benign prostatic 
hyperplasia (BPH).
Proportion of regulatory T cells (CD4 + CD25 + 
FoxP3 +) was significantly higher in patients with PCa 
compared to the proportion of Tregs in the prostate tissue 
of patients with BPH (Figure 3).
NK cells (CD3-CD56+) were statistically significant-
ly augmented in patients with BPH in comparison with 
patients with PCa, as well as the percentage of CD3-CD-
56dim+ cells, while in subpopulation of CD3-CD56bright+ 
was not statistically significantly differences (Figure 4).
Comparing the proportion of NKT cells in prostatic 
tissue of patients with BPH and PCa we noted less, but 
not statistically significantly reduced proportion of NKT 
cells in prostatic tissue of patients with PCa in comparison 
with patients who suffer of BPH:
DISCUSSION
Chronic inflammation has been shown may play a key 
role in the pathogenesis of BPH and could be associated 
with the development of PCa. Numerous studies in ani-
mal models and humans have shown that the chronic 
inflammation is one of the important factors in the de-
velopment of cancers such as pancreatic cancer, colorectal 
cancer or gastric cancer (22-24). Infiltration of tumor cells 
correlates with positive outcome of treatment. In patients 
with ovarian and colorectal cancer have been shown 
lower density of CD3 + cells in the tissue around the tu-
mor, what may reduce the survival of these patients com-
pared to patients in whom high density of infiltrating 
CD3 + cells were noticed (25, 26). Although in the tissue 
of the prostate cancer was observed infiltration of lym-
phocytes, outcome of these patients does not correlate 
with the density of their infiltration (27, 28). In our stud-
ies we observed an infiltration of prostate tissues of pa-
tients with PCa with T lymphocytes, NK cells and NKT 
cells, but their proportion was smaller in comparison with 
the frequency of these cells in prostate tissue in patients 
with BPH, especially we found a small proportion of NK 
cells and their CD3-CD56dim + subpopualation in pros-
tate tissue of patients with PCa. This small proportion of 
NK cells, particularly its cytotoxic CD3-CD56dim + 
subpopulation, could be one possible reason for the pro-
gression of PCa. It seems that the infiltration of T lym-
phocytes in prostate tissue of patients with PCa, what we 
observed in our study, may be associated with slower pro-
gression of tumor growth. A similar observation was no-
Figure 3. Proportion of  Tregs (CD4 + CD25 + FoxP3 +) in patients 
with BPH and Pca.
Figure 4. NK cells (CD3-CD56+) and its subpopulation of CD3-CD56dim+ cells and CD3-CD56bright+ in patients with BPH and Pca. 
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ticed in patients with small cell lung cancer, where a large 
number of tumor infiltrating lymphocytes, especially 
CD3 + CD8 + cells was observed in patients with mark-
edly smaller tumor size (29). However, since the cells were 
also found in the tissue of BPH, the question still stays: 
are these infiltrating lymphocytes in the prostate tissue of 
patients with PCa reflection of nonspecific chronic in-
flammation or are involved in the immune response 
against tumor.
The important role in the progression of PCa may have 
an increased proportion of CD4+ CD25+FoxP3+ regula-
tory T cells in the prostate tissue and in peripheral blood 
of patients with PCa (30). Many studies have shown that 
CD4+ T regulatory cells that constitutively express the 
high affinity receptor for IL-2 (CD25) and the transcrip-
tion factor FoxP3 play an important role in the suppres-
sion of effective anti-tumor immune response. Numerous 
studies have shown a high level of CD4+CD25+FoxP3+ 
regulatory T cells in patients with hematological malig-
nancies (31), in patients with lung cancer, ovarian cancer 
(32-34), in patients with melanoma (35), colorectal cancer 
(36-38), as well as in patients with squamous cell carci-
noma of the head and neck (39), hepatocellular carcinoma 
(40), breast cancer and carcinoma of the pancreas (41). 
There are differences between secretions of innate im-
mune cells during different pain management techniques 
in patients after colorectal cancer surgery (42, 43). In our 
research we have found increased levels of Tregs in pros-
tate tissue, as well as in peripheral blood (30). These re-
sults clearly indicate that increased levels of T regulatory 
cells in patients with PCa may stimulate the spread of 
tumors at the system level. On local level, increased infil-
tration of prostate tissue with T regulatory cells were 
found in patients with PCa. Another possible reason for 
ineffective anti-tumor activity of prostatic infiltrating 
lymphocytes of patients with PCa would be inadequate 
expression and regulation of cytotoxic molecules such as 
perforin. Perforin is known as a rapid mediator with cy-
totoxic activities which perform their effect by forming 
pores on the surface of the target (infected or tumor) cells. 
In our research we did not find statistically significant 
differences in the expression of perforin in the peripheral 
blood of patients with PCa compared to patients with 
BPH or control group, but we noticed extremely low ex-
pression of perforin in lymphocyte subpopulations in 
prostatic tissue of patients with PCa (44). It is assumed 
that the local microenvironment is responsible for its ex-
pression and regulation.
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